← Back to guidelines
Pediatrics7 papers

Cholestasis-edema syndrome, Norwegian type

Last edited: 4/15/2026

Overview

Aagenaes syndrome, also known as lymphoedema cholestasis syndrome 1 (LCS1), is an autosomal recessive inherited disorder characterized by neonatal cholestasis, intermittent cholestatic episodes throughout life, and progressive lymphoedema. 1

Diagnosis

  • Key Diagnostic Criteria: Neonatal onset of cholestasis, intermittent episodes of cholestasis in childhood and adulthood, development of lymphoedema.
  • Recommended Tests: Elevated alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and serum bile acids indicative of cholestasis.
  • Grading: Biochemical markers help monitor disease activity; liver biopsy may be necessary for assessing cirrhosis progression. 1
  • Management

  • First-Line Treatments: Supportive care including hydration, nutritional support, and management of symptoms like pruritus.
  • Adjunctive Treatments: Ursodeoxycholic acid (UDCA) may be considered for cholestatic episodes, though specific dosing is not detailed in the provided abstracts. 1
  • Lymphoedema Management: Compression therapy, manual lymphatic drainage, and skin care to prevent infections and manage edema. 1
  • Special Populations

  • Pediatrics: Early intervention is crucial for managing cholestatic episodes and preventing complications like severe lymphoedema. 1
  • Comorbidities: Increased risk of cirrhosis leading to transplantation needs or mortality, particularly in infancy or early childhood. 1
  • Key Recommendations

  • Regular monitoring of liver function tests (ALP, GGT, serum bile acids) is essential for early detection of disease progression in LCS1 patients. (Evidence: Moderate 1)
  • Consideration of ursodeoxycholic acid for managing cholestatic episodes, though evidence for specific outcomes is limited. (Evidence: Weak 1)
  • Aggressive management of lymphoedema through multidisciplinary approaches is recommended to improve quality of life and prevent complications. (Evidence: Expert opinion 1)
  • References

    1 Drivdal M, Trydal T, Hagve TA, Bergstad I, Aagenaes O. Prognosis, with evaluation of general biochemistry, of liver disease in lymphoedema cholestasis syndrome 1 (LCS1/Aagenaes syndrome). Scandinavian journal of gastroenterology 2006. link

    Original source

    1. [1]
      Prognosis, with evaluation of general biochemistry, of liver disease in lymphoedema cholestasis syndrome 1 (LCS1/Aagenaes syndrome).Drivdal M, Trydal T, Hagve TA, Bergstad I, Aagenaes O Scandinavian journal of gastroenterology (2006)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG